- Home
- MDGL vs JAZZ Comparison
MDGL vs JAZZ Comparison
Compare MDGL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- JAZZ
- Stock Information
- Founded
- MDGL 2011
- JAZZ 2003
- Country
- MDGL United States
- JAZZ Ireland
- Employees
- MDGL N/A
- JAZZ N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- JAZZ Health Care
- Exchange
- MDGL Nasdaq
- JAZZ Nasdaq
- Market Cap
- MDGL 7.4B
- JAZZ 6.5B
- IPO Year
- MDGL N/A
- JAZZ 2007
- Fundamental
- Price
- MDGL $321.33
- JAZZ $122.44
- Analyst Decision
- MDGL Buy
- JAZZ Buy
- Analyst Count
- MDGL 14
- JAZZ 14
- Target Price
- MDGL $347.33
- JAZZ $174.14
- AVG Volume (30 Days)
- MDGL 654.8K
- JAZZ 670.7K
- Earning Date
- MDGL 10-31-2024
- JAZZ 11-06-2024
- Dividend Yield
- MDGL N/A
- JAZZ N/A
- EPS Growth
- MDGL N/A
- JAZZ 458.10
- EPS
- MDGL N/A
- JAZZ 7.04
- Revenue
- MDGL $76,813,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- MDGL N/A
- JAZZ $7.43
- Revenue Next Year
- MDGL $193.46
- JAZZ $6.39
- P/E Ratio
- MDGL N/A
- JAZZ $16.96
- Revenue Growth
- MDGL N/A
- JAZZ 5.23
- 52 Week Low
- MDGL $168.25
- JAZZ $99.06
- 52 Week High
- MDGL $368.29
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- MDGL 62.52
- JAZZ 57.02
- Support Level
- MDGL $272.72
- JAZZ $115.65
- Resistance Level
- MDGL $323.99
- JAZZ $128.99
- Average True Range (ATR)
- MDGL 19.26
- JAZZ 3.42
- MACD
- MDGL -2.73
- JAZZ -0.18
- Stochastic Oscillator
- MDGL 48.41
- JAZZ 59.78
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.